Stay updated with breaking news from Lilly Alliance. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® on risk of heart failure hospitalization and death in adults following a...
RIDGEFIELD - More than 35 million adults in the U.S. have chronic kidney disease . However, as many as 90% of them are unaware of their condition. This is despite clinical guidelines, which show that...
More than 35 million adults in the U.S. have chronic kidney disease (CKD). However, as many as 90% of them are unaware of their condition. This is despite clinical guidelines, which show that using two tests can help detect it. That's why Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced the ...
/PRNewswire/ -- This World Heart Day, the World Heart Federation (WHF) is urging all sectors and citizens to join forces and take down cardiovascular disease...
The Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has granted a positive opinion recommending Jardiance empagliflozin for the treatment of adults with chronic kidney disease CKD Boehringer Ingelheim and Eli Lilly and Company NYSE LLY announced today.1